Table 2. Results of univariate analysis: Means, number, and p-values of background factors of patients treated with the TPF regimen (N = 87).
| Background factors | Mean ± SD | p-value |
| Age (years) | 62.9 ± 8.3 | 0.78 |
| BMI (kg/m2) | 19.9 ± 2.8 | 0.19 |
| Cisplatin dose (mg/m2) | 52.6 ± 8.2 | 0.02 |
| Clinical data | ||
| White blood cell (×103/μL) | 66.2 ± 30.1 | 0.03 |
| Hemoglobin (g/dl) | 13.0 ± 2.0 | 0.29 |
| Platelet (×103/μL) | 24.3 ± 9.3 | 0.38 |
| Creatinine (mg/dL) | 0.7 ± 0.1 | < 0.001 |
| Albumin (g/dL) | 3.8 ± 0.5 | 0.81 |
| Sodium (mg/dL) | 140.2 ± 2.2 | 0.34 |
| Potassium (mg/dL) | 4.1 ± 0.4 | 0.32 |
| Chlorine (mg/dL) | 103.2 ± 2.8 | 0.27 |
| Background factors | No. (%) | p-value |
| Male gender | 76 (87.4) | 0.78 |
| History of smoking | 64 (74.4) | 0.91 |
| Diagnosis | ||
| Diabetes mellitus | 8 (9.2) | 0.25 |
| Hypertension | 28 (32.2) | 0.77 |
| Hyperlipidemia | 10 (11.5) | 0.05 |
| Hyperuricemia | 2 (2.3) | 0.04 |
| Cardiovascular disease | 12 (13.8) | 0.84 |
| Use of drug with nephrotoxicity | ||
| NSAIDs | 30 (34.5) | <0.01 |
| Antibiotics | 5 (5.8) | 0.83 |
| MgO | 8 (9.2) | 0.20 |
| Contrast media | 0 (0.0) | |
| Calcium channel blockers | 24 (27.6) | 0.46 |
| RAS inhibitors | 12 (13.8) | 0.38 |
| Other antihypertensive agents | 3 (3.5) | 0.91 |
| Cancer type | ||
| Head and neck | 80 (92.0) | 0.32 |
| Esophageal | 7 (8.0) | 0.32 |
| Cancer stage | ||
| 1 / 2 / 3 / 4 | 1(1.2) / 12(13.8) / 16(18.4) / 58(66.7) | 0.23 |
TPF, docetaxel, cisplatin, and 5-fluorouracil; BMI, body mass index; NSAIDs, nonsteroidal anti-inflammatory drugs; MgO, magnesium oxide; RAS, renin-angiotensin system.